RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among heart failure patients with left ventricular ejection fraction greater than or equal to 40% hospitalized due to an episode of acute decompensated Heart Failure (REDEFINE-HF) - 202301CPC
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonist (sMRA).
Combined Efficacy and Safety of an Early, Intensive, Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure (CONFIRMATION-HF)
Combination therapy with finerenone with empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Telmisartan and Walking Performance in Peripheral Artery Disease
Article
作者: Beckman, Joshua A. ; Hess, Connie ; Bonaca, Marc P.
2020-03-03·Clinical Toxicology
In reply to Dr. Shah and Dr. Beuhler
Letter
作者: Gerardo, Charles J. ; Lavonas, Eric J. ; Anderson, Victoria E.
A polemic in response to Drs. Shah and Beuhler is given.Drs. Shah and Beuhler analyzed timing of Fab antivenom administration, and randomized clin. trial [RCT] from which this anal. was derived.However, authors believe that it is appropriate to incorporate evidence of benefit from early treatment into shared decision-making that includes patient-centered discussions of benefits, risk,and cost.
2020-03-01·Clinical Chemistry1区 · 医学
Clinical Relevance of the 99th Percentile Upper Reference Limit for High-Sensitivity Cardiac Troponin Assays
